First promising in vivo experiments in mice demonstrated that combining aAPC technology with anti-PD-1 ICI immunotherapy synergistically stimulated antigen-specific proliferation of cytotoxic T cells, delayed murine melanoma growth, and extended survival, while either treatment alone had no effect [83]. Here, PDCD1 is linked to melanoma.